AccessibilityHelpAbout Us
Vicapsys Life Sciences logo

Vicapsys Life Sciences(OTC) VICP

Market Cap$32.37MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-71%
5 Year+300%
1 Year-44%
1 Month-31%
$1.00
+0.00%
+0.00Today
Vicapsys Life Sciences last closing stock price
MetricPriceDate
Last closeUSD 1.002026-09-01
Vicapsys Life Sciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-31.03%USD 1.452026-08-20
1 month-31.03%USD 1.452026-07-28
3 month-31.51%USD 1.462026-04-09
Year to date-33.33%USD 1.502025-12-11
1 year-43.5%USD 1.772025-08-07
3 year+0%USD 1.002023-08-31
5 year+300%USD 0.252021-09-02
Since inception-71.43%USD 3.502018-01-05

Vicapsys Life Sciences Financials at a Glance

Market Cap

$32.37MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$758.63K

EPS (TTM)

$0.00

P/E Ratio

-40.16

Dividend

$0.00

Beta (Volatility)

35021.65 (High)

Price

$1.00

Volume

2,600

Open

$0.70

Previous Close

$1.00

Daily Range

$0.70 - $1.00

52-Week Range

$0.15 - $1.77

Estimated Earnings Date

Jul 20, 2026

VICP News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Vicapsys Life Sciences

Vicapsys Life Sciences, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for transplantation and associated stem-cell applications. The company is advancing its proprietary VICAPSYN product and the VYBRIN compound, targeting critical medical needs in wound healing and post-surgical complications.

Products and Services
  • VICAPSYN: A product aimed at enhancing transplant therapies
  • VYBRIN: Investigated for preventing post-surgical adhesions and promoting wound healing
  • Research and development in stem-cell applications for various medical conditions
Growth Outlook
  • VICAPSYN is positioned to address significant market needs in transplantation
  • VYBRIN's potential applications could capture a share of the wound care market
  • Ongoing research may lead to new therapeutic avenues and partnerships
Financial Highlights
  • Recent quarterly net income of -$104,569 reflects ongoing investment in R&D
  • Cash and cash equivalents increased to $132,542, indicating improved liquidity
  • Trailing twelve months show a consistent focus on operational efficiency despite losses
Vicapsys Life Sciences, Inc. operates in a dynamic sector with a focus on unmet medical needs. The company's commitment to developing innovative therapies positions it well for future growth. The ongoing development of VICAPSYN and VYBRIN highlights the potential for significant advancements in transplantation and wound care. Financially, while the company has reported losses, recent increases in cash reserves suggest a strategic focus on enhancing liquidity and operational capabilities. Investors may find the company's innovative approach and market potential appealing as it navigates the complexities of the biotechnology landscape.
AI Generated • Sep 5, 2026

Industry

Biotechnology

Sector

Health Care

Employees

2

CEO

Federico Luis Pier, MBA

Website

vicapsys.com

Headquarters

Suwanee, GA 30024, US

VICP Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

8.65%

Return on Capital

N/A

Return on Assets

-215.78%

Earnings Yield

-2.49%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$32.37MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

32.37M

Volume

2.60K

Avg. Volume

47.594

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$697.24K

EBITDA

-$697.24K

Operating Cash Flow

$210.06K

Capital Expenditure

-$3.00

Free Cash Flow

$210.06K

Cash & ST Invst.

$132.54K

Total Debt

$624.35K

Vicapsys Life Sciences Performance Analysis

Vicapsys Life Sciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Vicapsys Life Sciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32024-09-30N/A
Q42024-12-31N/A
Q12025-03-31N/A
Q12026-03-31N/A
Vicapsys Life Sciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.03141.0%
20232023-12-31USD -0.035.9%
20242024-12-31USD -0.03-15.8%
20252025-12-31USD -0.02-32.3%
Vicapsys Life Sciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32024-09-30-23.2%
Q42024-12-31-5.8%
Q12025-03-3130.1%
Q12026-03-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$32.37MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$16.19M

N/A

Employees

2

N/A

Net Income

-$104.57K

+45.0%

EBITDA

-$96.32K

+37.5%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$132.54K

+154018.6%

Total Debt

$624.35K

+35.2%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$624.35K

+35.2%

Return on Assets

-2.16%

N/A

Return on Invested Capital

7.59%

N/A

Free Cash Flow

-$5.09K

+93.8%

Operating Cash Flow

-$5.09K

+93.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SNANFSona Nanotech Inc.
$0.25+3.31%
ACHFFArch Biopartners Inc.
$0.68-8.05%
OTLCOncotelic Therapeutics, Inc.
$0.03-4.28%
INNMFAmplia Therapeutics Limited
$0.10+5.10%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$104.47+0.09%
NVDANvidia
$225.73-0.02%
ATAIAtaiBeckley
$7.28-0.01%
NOKNokia
$10.65+0.06%

Questions About VICP

What is the current price of Vicapsys Life Sciences?

Vicapsys Life Sciences is trading at $1.00 per share.

What is the 52-week range for Vicapsys Life Sciences?

Over the past 52 weeks, Vicapsys Life Sciences has traded between $0.15 and $1.77.

How much debt does Vicapsys Life Sciences have?

As of the most recent reporting period, Vicapsys Life Sciences reported total debt of $624.35K.

How much cash does Vicapsys Life Sciences have on hand?

Vicapsys Life Sciences reported $132.54K in cash and cash equivalents in its most recent financial results.

What is Vicapsys Life Sciences’s dividend yield?

Vicapsys Life Sciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services